Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT2 receptor

Sala, 1998, Leukotrienes: lipid bioeffectors of inflammatory reactions, Biochemistry, 63, 84 Capra, 2015, Transcellular biosynthesis of eicosanoid lipid mediators, Biochim Biophys Acta, 1851, 377, 10.1016/j.bbalip.2014.09.002 Sala, 1993, Formation of sulphidopeptide-leukotrienes by cell–cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit, Br J Pharmacol, 110, 1206, 10.1111/j.1476-5381.1993.tb13943.x Sala, 2000, Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness, Circulation, 101, 1436, 10.1161/01.CIR.101.12.1436 Sala, 1996, Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit, Blood, 87, 1824, 10.1182/blood.V87.5.1824.1824 Di Gennaro, 2004, Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes, FASEB J, 18, 842, 10.1096/fj.03-0599fje Dahlen, 1980, Leukotrienes are potent constrictors of human bronchi, Nature, 288, 484, 10.1038/288484a0 Folco, 2000, Leukotrienes in cardiovascular diseases, Am J Respir Crit Care Med, 161, S112, 10.1164/ajrccm.161.supplement_1.ltta-22 Capra, 2013, Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke, Med Res Rev, 33, 364, 10.1002/med.21251 Letts, 1987, Leukotrienes: role in cardiovascular physiology, Cardiovasc Clin, 18, 101 Lefer, 1988, Thromboxane A2 and leukotrienes are eicosanoid mediators of shock and ischemic disorders, Prog Clin Biol Res, 264, 101 Vigorito, 1997, Metabolic and hemodynamic effects of peptide leukotriene C4 and D4 in man, Int J Clin Lab Res, 27, 178, 10.1007/BF02912454 Back, 2011, International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions, Pharmacol Rev, 63, 539, 10.1124/pr.110.004184 Norel, 2004, The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues, Pharmacol Ther, 103, 81, 10.1016/j.pharmthera.2004.05.003 Laidlaw, 2012, Cysteinyl leukotriene receptors, old and new; implications for asthma, Clin Exp Allergy, 42, 1313, 10.1111/j.1365-2222.2012.03982.x Allen, 1992, Effects of leukotrienes C4 and D4 on human isolated saphenous veins, Br J Clin Pharmacol, 34, 409 Ortiz, 1995, Leukotriene receptors on human pulmonary vascular endothelium, Br J Pharmacol, 115, 1382, 10.1111/j.1476-5381.1995.tb16627.x Datta, 1995, Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells, Circulation, 92, 3304, 10.1161/01.CIR.92.11.3304 McIntyre, 1986, Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils, Proc Natl Acad Sci U S A, 83, 2204, 10.1073/pnas.83.7.2204 Pedersen, 1997, Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism, J Pharmacol Exp Ther, 281, 655 Zhao, 2004, The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm, Nat Med, 10, 966, 10.1038/nm1099 Uzonyi, 2006, Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells, Proc Natl Acad Sci U S A, 103, 6326, 10.1073/pnas.0601223103 Carnini, 2011, Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor, FASEB J, 25, 3519, 10.1096/fj.10-177030 Maciag, 1982, High and low molecular weight forms of endothelial cell growth factor, J Biol Chem, 257, 5333, 10.1016/S0021-9258(19)83778-X Gordon, 1983, Long-term culture of human endothelial cells, In Vitro, 19, 661, 10.1007/BF02628957 Garcia, 1997, Synthesis and biological evaluation of 14,15-dehydro-LTA(4) analog, Bioorg Med Chem Lett, 7, 105, 10.1016/S0960-894X(96)00598-7 Rabiet, 1996, Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization, Arterioscler Thromb Vasc Biol, 16, 488, 10.1161/01.ATV.16.3.488 Grynkiewicz, 1985, A new generation of Ca2+ indicators with greatly improved fluorescence properties, J Biol Chem, 260, 3440, 10.1016/S0021-9258(19)83641-4 De Curtis, 1994, Multifocal spontaneous epileptic activity induced by restricted bicuculline ejection in the piriform cortex of the isolated guinea pig brain, J Neurophysiol, 71, 2463, 10.1152/jn.1994.71.6.2463 1996 Sala, 1996, Release of leukotriene A4 versus leukotriene B4 from human polymorphonuclear leukocytes, J Biol Chem, 271, 17944, 10.1074/jbc.271.30.17944 DeLean, 1978, Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves, Am J Physiol, 235, E97 Capra, 2003, Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells, Prostaglandins Other Lipid Mediat, 71, 235, 10.1016/S1098-8823(03)00045-5 Mehta, 2001, Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function, J Biol Chem, 276, 22614, 10.1074/jbc.M101927200 Ridley, 1992, The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors, Cell, 70, 389, 10.1016/0092-8674(92)90163-7 Spindler, 2010, Role of GTPases in control of microvascular permeability, Cardiovasc Res, 87, 243, 10.1093/cvr/cvq086 Scott, 2010, Label-free whole-cell assays: expanding the scope of GPCR screening, Drug Discov Today, 15, 704, 10.1016/j.drudis.2010.06.008 Peters, 2009, Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity, J Biomol Screen, 14, 246, 10.1177/1087057108330115 Dunn, 2001, Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma, Drugs, 61, 285, 10.2165/00003495-200161020-00012 Keam, 2003, Pranlukast: a review of its use in the management of asthma, Drugs, 63, 991, 10.2165/00003495-200363100-00005 Heise, 2000, Characterization of the human cysteinyl leukotriene 2 receptor, J Biol Chem, 275, 30531, 10.1074/jbc.M003490200 Allen, 1998, Differential leukotriene constrictor responses in human atherosclerotic coronary arteries, Circulation, 97, 2406, 10.1161/01.CIR.97.24.2406 Kamohara, 2001, Functional characterization of cysteinyl leukotriene CysLT(2) receptor on human coronary artery smooth muscle cells, Biochem Biophys Res Commun, 287, 1088, 10.1006/bbrc.2001.5695 Sjostrom, 2003, Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells, Arterioscler Thromb Vasc Biol, 23, e37, 10.1161/01.ATV.0000082689.46538.DF Mita, 2001, Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils, Clin Exp Allergy, 31, 1714, 10.1046/j.1365-2222.2001.01184.x Lotzer, 2003, Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate 5-lipoxygenase-dependent circuits of inflammation and atherogenesis, Arterioscler Thromb Vasc Biol, 23, e32, 10.1161/01.ATV.0000082690.23131.CB Hui, 2004, Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure, Circulation, 110, 3360, 10.1161/01.CIR.0000147775.50954.AA Jiang, 2008, Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury, Am J Pathol, 172, 592, 10.2353/ajpath.2008.070834 Ni, 2011, A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice, J Pharmacol Exp Ther, 339, 768, 10.1124/jpet.111.186031 Beller, 2004, Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice, J Biol Chem, 279, 46129, 10.1074/jbc.M407057200 Fitzpatrick, 1982, Albumin stabilizes leukotriene A4, J Biol Chem, 257, 4680, 10.1016/S0021-9258(18)34575-7 Fang, 2007, Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia, Neurosci Lett, 412, 78, 10.1016/j.neulet.2006.10.065 Huang, 2008, Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation, Glia, 56, 27, 10.1002/glia.20588 Sheng, 2006, Distinct roles of CysLT1 and CysLT2 receptors in oxygen glucose deprivation-induced PC12 cell death, Biochem Biophys Res Commun, 346, 19, 10.1016/j.bbrc.2006.05.023 Wang, 2006, Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression, Biochem Biophys Res Commun, 350, 399, 10.1016/j.bbrc.2006.09.057 Bogatcheva, 2002, Molecular mechanisms of thrombin-induced endothelial cell permeability, Biochem, 67, 75 Duah, 2013, Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors, Sci Rep, 3, 3274, 10.1038/srep03274 Ferris, 1991, Inositol trisphosphate receptor: phosphorylation by protein kinase C and calcium calmodulin-dependent protein kinases in reconstituted lipid vesicles, Proc Natl Acad Sci U S A, 88, 2232, 10.1073/pnas.88.6.2232 Mamedova, 2005, CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors, Biochem Pharmacol, 71, 115, 10.1016/j.bcp.2005.10.003 Woszczek, 2010, Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists, J Immunol, 184, 2219, 10.4049/jimmunol.0900071 Hay, 1987, Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways, J Pharmacol Exp Ther, 243, 474 Obata, 1992, In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues, Jpn J Pharmacol, 60, 227, 10.1254/jjp.60.227 Ravasi, 2000, A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma, Mol Pharmacol, 57, 1182 Capra, 2007, Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends, Med Res Rev, 27, 469, 10.1002/med.20071 Nobili, 2012, Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease, PLoS ONE, 7, e41786, 10.1371/journal.pone.0041786 Riccioni, 2008, Leukotriene modifiers in the treatment of cardiovascular diseases, J Leukoc Biol, 84, 1374, 10.1189/jlb.0808476 Ingelsson, 2012, Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease, J Allergy Clin Immunol, 129, 702, 10.1016/j.jaci.2011.11.052 Toki, 1988, The effects of lipoxygenase inhibitor and peptidoleukotriene antagonist on myocardial injury in a canine coronary occlusion-reperfusion model, Prostaglandins, 35, 555, 10.1016/0090-6980(88)90031-7 Hock, 1992, Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion, Cardiovasc Res, 26, 1206, 10.1093/cvr/26.12.1206 Hahn, 1992, Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury, J Pharmacol Exp Ther, 260, 979 Ito, 1989, Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart, Jpn Circ J, 53, 1115, 10.1253/jcj.53.1115 Beller, 2004, Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis, Proc Natl Acad Sci U S A, 101, 3047, 10.1073/pnas.0400235101 Jiang, 2007, CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells, Blood, 110, 3263, 10.1182/blood-2007-07-100453